Trial Profile

A 57-Week, Multicenter, Active-treatment, Open-label Extension Trial of CVL-865 as Adjunctive Therapy in Adults With Drug-Resistant Focal Onset Seizures

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 18 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darigabat (Primary)
Indications Seizures
Focus Adverse reactions; Therapeutic Use
Sponsors Cerevel Therapeutics

Most Recent Events

11 Dec 2025 Status changed from completed to discontinued.
07 Jan 2025 Status changed from active, no longer recruiting to completed.
01 Aug 2024 According to an AbbVie media release, AbbVie has acquired Cerevel Therapeutics.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com